Summit Therapeutics Inc. Increase (Decrease) in Prepaid Expense
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Prepaid Expense of -$572.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2024-10-30
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2024-09-30 was $181.00K.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2024-06-30 was -$3.54M, a 172.41% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2024-03-31 was $2.79M.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2023-12-31 was -$2.64M.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for fiscal 2023 was $914.00K.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for fiscal 2022 was -$5.11M.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for fiscal 2021 was -$2.35M, a 624.61% decline from fiscal 2020.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense for fiscal 2020 was $447.00K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 11 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $181.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$3.36M derived: sum of 2 quarters · filed 2024-10-30 | -$572.00K 10-Q · filed 2024-10-30 | -$3.21M derived: sum of 4 quarters · filed 2024-10-30 | |
| 2024-06-30 | -$3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$753.00K 10-Q · filed 2024-08-06 | -$3.39M derived: sum of 3 quarters · filed 2024-08-06 | -$4.40M derived: sum of 4 quarters · filed 2024-10-30 | |
| 2024-03-31 | $2.79M 10-Q · filed 2024-05-01 | $152.00K derived: sum of 2 quarters · filed 2024-05-01 | -$859.00K derived: sum of 3 quarters · filed 2024-10-30 | $4.04M derived: sum of 4 quarters · filed 2024-10-30 | |
| 2023-12-31 | -$2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$3.65M derived: sum of 2 quarters · filed 2024-10-30 | $1.25M derived: sum of 3 quarters · filed 2024-10-30 | $914.00K 10-K · filed 2024-02-20 | |
| 2023-09-30 | -$1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $3.88M derived: sum of 2 quarters · filed 2024-10-30 | $3.55M 10-Q · filed 2024-10-30 | $3.45M derived: sum of 4 quarters · filed 2024-10-30 | |
| 2023-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.57M 10-Q · filed 2024-08-06 | $4.46M derived: sum of 3 quarters · filed 2024-08-06 | $689.00K derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$331.00K 10-Q · filed 2024-05-01 | -$432.00K derived: sum of 2 quarters · filed 2024-05-01 | -$4.21M derived: sum of 3 quarters · filed 2024-05-01 | -$2.76M derived: sum of 4 quarters · filed 2024-05-01 | |
| 2022-12-31 | -$101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$3.88M derived: sum of 2 quarters · filed 2024-02-20 | -$2.42M derived: sum of 3 quarters · filed 2024-02-20 | -$5.11M 10-K · filed 2024-02-20 | |
| 2022-09-30 | -$3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.32M derived: sum of 2 quarters · filed 2023-11-07 | -$5.01M 10-Q · filed 2023-11-07 | -$6.29M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.23M 10-Q · filed 2023-08-09 | -$2.51M derived: sum of 3 quarters · filed 2023-08-09 | $392.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$2.68M 10-Q · filed 2023-05-11 | -$3.96M derived: sum of 2 quarters · filed 2023-05-11 | -$1.06M derived: sum of 3 quarters · filed 2023-05-11 | -$3.39M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.62M derived: sum of 2 quarters · filed 2023-03-09 | -$707.00K derived: sum of 3 quarters · filed 2023-03-09 | -$2.35M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $573.00K derived: sum of 2 quarters · filed 2022-11-09 | -$1.06M 10-Q · filed 2022-11-09 | $813.00K derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-06-30 | -$2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$3.97M 10-Q · filed 2022-08-11 | -$2.09M derived: sum of 3 quarters · filed 2022-12-21 | -$3.87M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-03-31 | -$1.64M 10-Q · filed 2022-05-11 | $240.00K derived: sum of 2 quarters · filed 2022-12-21 | -$1.54M derived: sum of 3 quarters · filed 2022-12-21 | -$1.66M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2020-12-31 | $1.88M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $99.00K derived: sum of 2 quarters · filed 2022-12-21 | -$25.00K derived: sum of 3 quarters · filed 2022-12-21 | $447.00K 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | -$1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$1.90M derived: sum of 2 quarters · filed 2021-11-15 | -$1.43M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $348.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $472.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | -$952.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | -$9.71M derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$2.73M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $6.99M 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | $1.26M 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $7.55M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |